transforming growth factor(alpha)-pseudomonas aeruginosa exotoxin
Recombinant proteinexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Oct 1, 2003 (NCT00071539)
Timeline
Indications
Studied for
Mechanism of action
- Protransforming growth factor alphaBINDING AGENT
TGFA binding agent
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- tgfalpha-p aeruginosa exotoxin (38)
- tp38
- tp-38
- tp-38
- transforming growth factor(alpha)-pseudomonas aeruginosa exotoxin
- transforming growth factor(alpha)-pseudomonas aeruginosa exotoxin (38)
- transmid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00104091 | Phase 2 | Dec 1, 2004 | Teva |
| NCT00088400 | Phase 3 | Jul 1, 2004 | National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT00083447 | Phase 3 | May 1, 2004 | Xenova Biomedix |
| NCT00071539 | Phase 2 | Oct 1, 2003 | Teva |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Teva | For profit | 2 | 2 | 1 | 2003 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 2004 |
| Xenova Biomedix | For profit | 1 | 1 | 1 | 2004 |
3 organizations
Page 1 / 1